Back to announcement
20250130_SDPC_Laporan Informasi dan Fakta Material_31848234_lamp1.pdf
Other Text extracted SDPCSource file signed link, expires in 15 minutes
Extracted text 2
Page 1 OCR 0.914
MP PT MILLENNIUM PHARMACON INTERNATIONAL Tbk No. 1 150/MPI/DIR/I/2025 Jakarta, 30 January 2025 Lampiran : - Perihal : Laporan Informasi atau Fakta Material Yth. Kepala Eksekutif Pengawas Pasar Modal Otoritas Jasa Keuangan Gedung Soemitro Djojohadikusumo Jalan Lapangan Banteng Timur 2-4 Jakarta 10710 Sehubungan dengan Peraturan Otoritas Jasa Keuangan (OJK) no: 45 Tahun 2024 tanggal 31 Desember 2024 tentang Tentang Pengembangan dan Penguatan Emiten dan Perusahaan Publik, dengan ini kami menyampaikan Laporan Informasi atau Fakta Material sebagai berikut : In reference to Otoritas Jasa Keuangan (OJK) Regulation No.: 45 of 2024 dated 31 December 2024 regarding DDevelopment and Strengthening of Issuers and Public Companies, we hereby disclose the information and Material Fact as follow: Nama Emiten atau Perusahaan Publik//ssuer: PT Millennium Pharmacon International Tbk (“Perseroan”) Bidang Usaha/Scope of Business 1 Distribusi produk farmasi, suplemen makanan dan alat kesehatan Telepon/Phone 1 (021)2708 5961, (021) 2708 5964 Faksimili/Facsimile 1 (021) 2708 5958 Alamat surat elektronik/e-mail 1 Investor.relation@mpi-pharmaniaga.co.id 1 | Tanggal kejadian Date Event 24 January 2025 January 24", 2025 2 | Jenis Informasi atau Fakta Material Type of Information or Material Facts Penandatanganan Perubahan dan Penegasan | Signing of Amendments and Reaffirmation of Kembali Perjanjian Kredit Credit Agreements 3 | Uraian Informasi atau Fakta Material Description of Information or Material Facts a) Pihak-pihak yang melakukan perjanjian: | a) Parties to the agreement : Company and PT | | Perseroan dan PT Bank UOB Indonesia, Bank UOB Indonesia, b) Bank telah menyetujui perpanjangan | h) The Bank has approved the renewal of' ine | fasilitas kredit dengan total limit sejumlah credit facilities with total limit facility | Rp370 Miliar kepada Perseroan: amounted to IDR370 billion to the company, c) Perubahan Jangka waktu perjanjian telah | c) Changes the Agreement Period has been disetujui diperpanjang sampai dengan approved to be extended until January 29th, tanggal 29 Januari 2026. 2026. 4 | Dampak kejadian, informasi atau fakta | Impact for information or ik Crown Bungur Artemateriatloortersebut oo terhadap kegiatan | trowards operational activity, legal, angial Jl. Sultan Iskandar Muda No. 18, Jakarta 12240, Indonesia " XKAN Phone : #6221 27085961
Page 2 OCR 0.885
MPI PT MILLENNIUM PHARMACON INTERNATIONAL Tbk operasional, hukum, kondisi keuangan, atau | condition or business continuity of Issuer or or kelangsungan — usaha Emiten atau | Public Company Perusahaan Publik Fasilitas Kredit ini menunjang kegiatan usaha | This Credit Facility supports the company 's perseroan. business activities. 5 | Keterangan lain-lain Other Information Tidak ada None Hormat kami, PT Millennium Pharmacon International Tbk PT.WLLENMuwPianmAcoN mTERMATIONAL Tox Nama? Mohahnad Fazly Hassan Jabatan: Direktur Tembusan: PT Bursa Efek Indonesia u.p. Yth. Direksi Crown Bungur Arteri 2-4th Floors TN ES Jl. Sultan Iskandar Muda No. 18, Jakarta 12240, Indonesia TRACE Phone : #6221 27085961 Fax : #6221 27085958 MEMBER
Names mentioned 5 people and organisations named in the text · linked when the evidence is strong
unresolved
person
Nama? Mohahnad Fazly Hassan
· Jabatan: Direktur
p.2
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.